Teva says yes to M&A; GlycoMimetics snags $57.4M in IPO retry;

@FierceBiotech: Merck clears an FDA panel with its clot-fighting vorapaxar. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: Roche 's dealmakers at pRED will continue their global shopping spree in 2014. More | Follow @JohnCFierce

@DamianFierce: Sarepta still climbing on renewed hopes for eteplirsen. Article | Follow @DamianFierce

@EmilyMFierce: Per the FDA's new stance on antibacterials, here's a list of household products containing triclosan. | Follow @EmilyMFierce

> Israel's Teva Pharmaceutical ($TEVA) will be a bullish dealmaker under new CEO Erez Vigodman, according to CFO Eyal Desheh. Article

> GlycoMimetics ($GLYC) netted $57.4 million in its second try at an IPO, money it'll use to fund the development of GMI-1271, an early-stage treatment for acute myeloid leukemia. News

> Houston's Bio-Path is raising $10 million to support Liposomal Grb-2, a Phase I treatment for blood cancers. More

Medical Device News

@FierceMedDev: Thermo nabs Chinese approval of $13.6B Life Tech merger. More | Follow @FierceMedDev

@MarkHFierce: Even N.Y. Sen. Chuck Schumer spilled the beans about Carlyle Group's bid for J&J's Ortho Clinical diagnostics arm. Story | Follow @MarkHFierce

@MichaelGFierce: Cynapsus' sublingual strip for severe Parkinson's reduces side effects in a study. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Integra finalizes $235M deal for Covidien's surgical products line. News | Follow @EmilyWFierce

@GalenMoore: Bio-Path Holdings is raising $10M for its cancer drug delivery tech. Release | Follow @GalenMoore

> Medtronic must pay Edwards at least $394M in heart valve patent trial defeat. Report

> Illumina will concoct a companion Dx for an Amgen colon cancer drug. Item

Pharma News

@FiercePharma: FDA: The social media guidance puzzle will be complete by July. More | Follow @FiercePharma

@TracyStaton: Hungary joins the club of EU countries approving Novartis' generic version of GSK's blockbuster Advair. News | Follow @TracyStaton

@EricPFierce: FDA investigator assigned to Europol to fight fakes being hawked online by drug rings. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Allergan rides high on patent backing for key drugs Lumigan and Restasis. Article | Follow @CarlyHFierce

> Actavis is pulling out of China; CEO says it's 'not worth the aggravation.' News

> FDA: The social media guidance puzzle will be complete by July. Story

> Impatient Bidvest prods Adcock for a deal as tussle with rival bidder escalates. Report

> J&J takes Carlyle's $4B offer for its Ortho Diagnostics unit. Item

Pharma Manufacturing News

> Merck recalls all lots of Liptruzet shipped since its May debut. Story

> Ex-Fresenius employee says he was fired for raising red flags. Article

> Premier supports new FDA compounder oversight plan. Report

> FDA assigns an agent to Europol in its fight against fakes. More

> Sources: Ranbaxy asks the FDA to let it make generic Diovan in U.S. News

> Actavis selling China assets as it exits that country. Item

Vaccines News

> CDC, FDA studies link Merck and GSK rotavirus vaccines to bowel blockages. Story

> BIO and Sanofi are pushing the FDA to tweak its drug shortage rule for vaccines. Story

> A Dendreon consultant has raised $8M for a cancer vaccine startup. Story

> Buzz: Merck and Novartis trying to iron out details of their business unit swap. Story

> AC Immune begins first trial of a tau-targeting Alzheimer's vaccine. Story

> Astellas and Takeda continue to advance vaccine strategies. Item

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.